Seshu Tyagarajan Sells 14,322 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock

Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) CTO Seshu Tyagarajan sold 14,322 shares of the company's stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $7.22, for a total transaction of $103,404.84. Following the sale, the chief technology officer now directly owns 96,790 shares in the company, valued at approximately $698,823.80. The trade was a 12.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Seshu Tyagarajan also recently made the following trade(s):

• On Friday, November 29th, Seshu Tyagarajan sold 20,392 shares of Candel Therapeutics stock. The shares were sold at an average price of $4.56, for a total transaction of $92,987.52.

Candel Therapeutics Stock Down 13.4 %

Candel Therapeutics stock traded down $1.03 during trading on Friday, reaching $6.66. The stock had a trading volume of 1,899,373 shares, compared to its average volume of 1,683,500. Candel Therapeutics, Inc. has a 52-week low of $1.16 and a 52-week high of $14.60. The stock has a market cap of $216.32 million, a PE ratio of -3.85 and a beta of -1.20. The business has a 50 day moving average price of $6.58 and a 200 day moving average price of $6.27.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a "buy" rating and set a $19.00 target price (up from $11.00) on shares of Candel Therapeutics in a research note on Wednesday, December 18th.

Hedge Funds Weigh In On Candel Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of CADL. FMR LLC acquired a new position in Candel Therapeutics in the third quarter valued at approximately $46,000. Geode Capital Management LLC grew its position in shares of Candel Therapeutics by 12.8% in the 3rd quarter. Geode Capital Management LLC now owns 448,997 shares of the company's stock valued at $3,112,000 after buying an additional 51,111 shares during the last quarter. Barclays PLC grew its position in shares of Candel Therapeutics by 327.1% in the 3rd quarter. Barclays PLC now owns 28,688 shares of the company's stock valued at $199,000 after buying an additional 21,971 shares during the last quarter. State Street Corp lifted its position in Candel Therapeutics by 4.1% in the third quarter. State Street Corp now owns 492,005 shares of the company's stock valued at $3,410,000 after acquiring an additional 19,207 shares during the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new stake in Candel Therapeutics in the second quarter valued at $162,000. Institutional investors and hedge funds own 13.93% of the company's stock.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.